Study Details

Study on Enzalutamide and Flutamide in Patients with Castration Resistant Prostate Cancer

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred). ID

The unique identification code given to each clinical study upon registration at

Astellas Study ID

The unique identification code given by the study sponsor.


EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).



Prostate Cancer


These clinical trials happen after a drug or treatment has been approved for patients to take. Clinical trials in phase 4 usually take place over many years because researchers want to learn about long term use and safety of a drug or treatment.

Phase 4


20 years - N/A






A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


Trial Dates

Nov 2016 - Mar 2020


None (Open Label)

Enrollment number


A Randomized Phase IV Study Comparing Enzalutamide versus Flutamide in Castration-resistant prostate cancer (CRPC) Patients Who Have Failed Combined Androgen Blockade Therapy with Bicalutamide plus Androgen deprivation therapy (ADT)

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Study on Enzalutamide and Flutamide in Patients with Castration Resistant Prostate Cancer? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.


Site JP00032

Osaka, Japan

Site JP00022

Hamamatsu, Japan

Site JP00048

Sapporo, Japan

Site JP00031

Osaka, Japan

Site JP00044

Yokosuka, Japan

Site JP00030

Osakasayama, Japan

Site JP00050

Fukuoka, Japan

Site JP00001

Sapporo, Japan

Site JP00028

Hirakata, Japan

Site JP00038

Matsuyama, Japan

Site JP00040

Fukuoka, Japan

Site JP00025

Nagoya, Japan

Site JP00043

Ota, Japan

Site JP00017

Bunkyo-ku, Japan

Site JP00020

Yokohama, Japan

Site JP00035

Hiroshima, Japan

Site JP00019

Sagamihara, Japan

Site JP00052

Toyama, Japan

Site JP00055

Mito, Japan

Site JP00002

Sapporo, Japan

Site JP00021

Yokohama, Japan

Site JP00010

Chiba, Japan

Site JP00039

Fukuoka, Japan

Site JP00034

Ube, Japan

Site JP00049

Utsunomiya, Japan

Site JP00016

Shinagawa-ku, Japan

Site JP00011

Bunkyo-ku, Japan

Site JP00013

Koto-ku, Japan

Site JP00046

Kashihara, Japan

Site JP00054

Hakodate, Japan

Site JP00027

Suita, Japan

Site JP00024

Nagoya, Japan

Site JP00053

Chiba, Japan

Site JP00006

Nagano, Japan

Site JP00026

Kyoto, Japan

Site JP00014

Nakano-ku, Japan

Site JP00005

Maebashi, Japan

Site JP00033

Kurashiki, Japan

Site JP00018

Shinjuku-ku, Japan

Site JP00045

Isesaki, Japan

Site JP00029

Osaka, Japan

Site JP00008

Nagano, Japan

Site JP00009

Kitaadachi-gun, Japan

Site JP00051

Iizuka, Japan

Site JP00041

Nagasaki, Japan

Site JP00037

Tokushima, Japan

Site JP00042

Saga, Japan